Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.
Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.
Merck won the FDA's blessing for a next-generation HPV vaccine designed to usurp Gardasil, putting it in line for billions in revenue.
Investigators have suspended a Phase I study of NewLink Genetics' Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant's plans to quickly ramp up production.
Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.
Merck's Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.
Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.
Merck's pembrolizumab, sold as Keytruda, showed promising signs of efficacy in a particularly deadly brand of breast cancer, early data that could expand the use for a new class of treatments expected to take the market by storm.
Some analysts have pointed to Merck's hospital sales force and its 2,000 or so reps. Surely those experienced sales types can wring more sales out of Cubist's products than the much smaller Cubist group did.
Amgen and Merck have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.